{"id":24541,"date":"2023-01-13T16:25:00","date_gmt":"2023-01-13T21:25:00","guid":{"rendered":"https:\/\/www.diabete.qc.ca\/en\/news\/adultes-vivant-avec-le-diabete-de-type-2-recherches-etude-sur-la-prevention-des-evenements-cardiovasculaires\/"},"modified":"2023-05-30T14:13:15","modified_gmt":"2023-05-30T18:13:15","slug":"adults-living-with-type-2-diabetes-wanted-cardiovascular-event-prevention-study","status":"publish","type":"post","link":"https:\/\/www.diabete.qc.ca\/en\/news\/adults-living-with-type-2-diabetes-wanted-cardiovascular-event-prevention-study\/","title":{"rendered":"Adults living with Type 2 diabetes wanted \u2013 Cardiovascular event prevention study"},"content":{"rendered":"\n<p>Dr. Jean-Claude Tardif&#8217;s research team at the Montreal Heart Institute (MHI) is looking for people living with type 2 diabetes to participate in the COLCOT-T2D clinical study.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The purpose of the study<\/h2>\n\n\n\n<p>The purpose of this study is to determine if an anti-inflammatory agent (colchicine) and an anti-platelet agent (aspirin), combined or alone, can prevent cardiovascular events in type 2 diabetic patients who have never had a cardiovascular event.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The implication<\/h2>\n\n\n\n<p>Take the study medication daily, which is delivered to your home every 6 months. Follow-up is done by telephone or video contact, without hospital visits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The duration<\/h2>\n\n\n\n<p>Between 36 and 54 months.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Inclusion criteria<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Living with type 2 diabetes<\/li>\n\n\n\n<li>Aged between 50 and 80<\/li>\n\n\n\n<li>Have never suffered a cardiac event<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">For more information about the study or to participate:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>View the <strong><a href=\"https:\/\/www.diabete.qc.ca\/wp-content\/uploads\/2023\/01\/COLCOT-T2D_Poster_FR_v2.1_17-Jan-2023_Diabete-Qc.pdf\">full announcement<\/a><\/strong><\/li>\n\n\n\n<li>Visitez le site web&nbsp;<strong><a href=\"https:\/\/colcot-t2d.org\/en\" target=\"_blank\" rel=\"noreferrer noopener\">www.colcot-t2d.org<\/a><\/strong><\/li>\n\n\n\n<li>Call&nbsp;<strong>1 800-587-3389<\/strong><\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Jean-Claude Tardif&#8217;s research team at the Montreal Heart Institute (MHI) is looking for people living with type 2 diabetes to participate in the COLCOT-T2D clinical study. The purpose of the study The purpose of this study is to determine if an anti-inflammatory agent (colchicine) and an anti-platelet agent (aspirin), combined or alone, can prevent&hellip;<\/p>\n","protected":false},"author":1,"featured_media":31814,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"274,10802,12718,32,10257,12766","_relevanssi_noindex_reason":"","footnotes":""},"categories":[154,268],"tags":[],"class_list":["post-24541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recruitment-en","category-recrutement-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/posts\/24541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/comments?post=24541"}],"version-history":[{"count":5,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/posts\/24541\/revisions"}],"predecessor-version":[{"id":28126,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/posts\/24541\/revisions\/28126"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/media\/31814"}],"wp:attachment":[{"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/media?parent=24541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/categories?post=24541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.diabete.qc.ca\/en\/wp-json\/wp\/v2\/tags?post=24541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}